Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.
about
Microfluidic platform combining droplets and magnetic tweezers: application to HER2 expression in cancer diagnosis.Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.Determination of HER2 amplification status on tumour DNA by digital PCRShort-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy.The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer.Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance.The human epidermal growth factor receptor 2 (HER2).HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.NanoString nCounter® Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry.The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment.Divisional role of quantitative HER2 testing in breast cancer.Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women's breast cancer tumors.FISH in triple-negative breast cancer: a possible strategy for the future?Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization.HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.Relationship between gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
P2860
Q27316870-466C5CDA-5DD6-4EEA-A1EC-0C7D44042F14Q33623561-EC16C310-F268-42E0-9A6E-FE8C3D259F2EQ33739841-47F42F65-4173-4454-8F67-888D40157662Q35080338-7ED780D0-706D-418E-BFF8-F4D2AF5121B7Q35640863-02C0F82B-373C-4E36-B610-A06306676064Q35983341-7C2004B7-19E3-4F3E-9472-E4F3DD10350BQ36070547-BACD5EAD-EF21-4CE9-8E8C-C08E437E53D1Q36110190-9ACAEF36-DA25-4749-975C-65EF74533F35Q37019041-070F26F1-8442-4FB6-A6DD-08793EFDA5FCQ37932507-FEEEA660-2F43-488F-98B8-7EDAE9B3A00DQ38326102-05FBDE63-7B59-4438-A2CB-215306EBD935Q38612634-42CB8EA0-6C4B-4C1B-9171-52B4C0ECE3ECQ42316809-685DF2CA-2AE8-4BBE-821F-0FB251352BEAQ42366735-43A95E3F-1772-4A9F-A11F-1D879CCEE58AQ46431111-8DB54692-D004-410A-A202-B793FD5CD757Q46521614-22266CB0-88F1-4E91-809B-8CAE9B16BBC3Q48144691-97C25D9B-EB2A-4CE3-B3B6-CBB591492634Q48550447-FC41DB06-4F8E-4B6C-84E9-11E6A36EE84CQ50893707-9A96EA8B-4933-45E6-9C78-65D7E334944CQ53669221-D54BDC56-B230-4442-9219-C0AC7344022BQ58801931-A86ACF79-76F5-4D5A-B84B-BD25584E92E3
P2860
Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Immunohistochemical and molecu ...... and complementary approaches.
@ast
Immunohistochemical and molecu ...... and complementary approaches.
@en
type
label
Immunohistochemical and molecu ...... and complementary approaches.
@ast
Immunohistochemical and molecu ...... and complementary approaches.
@en
prefLabel
Immunohistochemical and molecu ...... and complementary approaches.
@ast
Immunohistochemical and molecu ...... and complementary approaches.
@en
P2093
P2860
P356
P1476
Immunohistochemical and molecu ...... and complementary approaches.
@en
P2093
A de Roquancourt
C de Bazelaire
E Bourstyn
F Amira-Bouhidel
P2860
P2888
P304
P356
10.1038/BJC.2011.135
P407
P577
2011-05-03T00:00:00Z